ArticleNPJ digital medicine2025
Trends and effectiveness of digital health management in postdischarge coronary artery disease across COVID19 pandemic.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The effectiveness of digital health management (DM) in post-discharge care for patients with coronary artery disease (CAD) remains insufficiently explored, particularly across public health emergencies. A total of 24,129 patients with CAD enrolled in the HeartMed Digital Management System were divided into DM or conventional management groups based on patient preference, and categorized into pre-COVID-19 (n = 13,473; 16.7% DM), COVID-19 (n = 5173; 80.3% DM), and post-COVID-19 (n = 5483; 86.2% DM) eras according to enrollment dates. For the primary endpoint, digital healthcare was significantly associated with lower all-cause mortality risk across all three periods after adjustment (HR: pre-COVID 0.23; COVID 0.52; post-COVID 0.58; all p < 0.001). No significant interaction was found in the protective effect of DM among the three eras (all interaction p > 0.05). Similar trends were observed for the secondary endpoints-readmission, MACE, and MACCE. Across all three pandemic phases, DM was consistently associated with improved clinical outcomes in post-discharge CAD populations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.